Bullish Case: BYRN at $3.68 has stabilized after the August slide (+1.7% over a month, +8.2% over sixty days). The IV surface shows volatility decaying from ~500 toward ~440 across the near grid and compressing at higher strikes (2.5→3.96), suggesting tail hedging demand is fading. If the next earnings cycle passes without a shock, mean reversion plus IV compression could lift price toward $4.50–5.00.

Bearish Case: The stock is down ~83% year-over-year and ~75% over two years; Helium's AI forecast is -6.0% with a 0.0 realized-correlation history. Near-dated IV near 440–500% signals the market still prices acute tail risk. Contango-free flat term structure, thin options volume, and wide spreads indicate no committed buyers — continued drift toward $3.00–3.25 remains the path of least resistance.

Potential Outcomes:

1. 40% — Continued drift to $3.00–$3.75 through Dec: falsifiable if put IV keeps dominating and no positive 8-K appears (validates Aug-18 bear call).
2. 30% — Range-bound $3.50–$4.25: falsifiable via flat guidance and stable volume.
3. 18% — Recovery to $4.50–$5.50 by Mar-2027: falsifiable via sequential revenue beat or distribution win; 5.00C (Mar, delta 0.44) reflects this tail.
4. 8% — Shock below $2.50: falsifiable via dilution/funding filing.
5. 4% — Contract/M&A pop >50%: falsifiable via press release.

September 19, 2026